Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

One-fifth of stem cell transplantation patients develop PTSD

Publish date:: June 9, 2020

Key clinical point: Approximately one-fifth of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation may develop posttraumatic stress disorder.

Major finding: Six months after transplantation, 18.9% of patients had symptoms of posttraumatic stress disorder.

Study details: An observational study involving 250 adults with hematologic malignancies who underwent hematopoietic stem cell transplantation.

Disclosures: The study was funded by the Lymphoma and Leukemia Society. The investigators disclosed additional relationships with Vector Oncology, Pfizer, AstraZeneca, and Gaido Health/BCG Digital Ventures.

Citation:

Griffith et al. ASCO 2020. Abstract # 7505.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Mixed Topics

Phase 1 study: Beta-blocker may improve melanoma treatment response,

REALITY trial supports restrictive transfusion in anemic MI,

Men occupy most leadership roles in medicine,

Study highlights benefits of integrating dermatology into oncology centers,

Tandem transplantation, long-term maintenance may extend MM remission,